Dividend16 May 2026, 03:30 pm
Tatva Chintan Approves ₹2 Final Dividend
AI Summary
The Board of Directors of Tatva Chintan Pharma Chem Limited approved a final dividend of ₹2 (20%) per equity share of ₹10 each for the financial year 2025-26, subject to shareholder approval at the upcoming Annual General Meeting. The board also approved the appointment of M/s. Zarna Thakar & Associates as Cost Auditor and RSM Astute Consultech Private Limited as Internal Auditor for FY 2026-27.
Key Highlights
- Final dividend of ₹2 per share (20%) approved for FY26.
- Dividend payout is subject to shareholder approval.
- Zarna Thakar & Associates appointed as Cost Auditor for FY27.
- RSM Astute Consultech appointed as Internal Auditor for FY27.
- Audited financial results for FY26 were approved.
Price Impact
More from TATVA